Temporal dynamics of MRD in 10 patients with high-risk DLBCL who experienced relapse during or after atezolizumab treatment. MRD assessment was performed using the clonoSEQ assay on cell-free DNA samples. MRD status is determined as either positive or negative based on the limit of detection (LOD) of the assay, which is individually calculated for each sample. The LOD represents the lowest level of residual tracked templates that can be reliably detected in at least 95% of samples.